Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clevudine + peginterferon
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
Clevudine + peginterferon is a combination therapy investigated for the treatment of chronic hepatitis B virus (HBV) infection. Clevudine is a nucleoside analog antiviral that inhibits HBV DNA polymerase through non-competitive inhibition by its triphosphate form, interfering with viral replication[6]. Peginterferon (specifically peginterferon alfa-2a) is a recombinant interferon conjugated to polyethylene glycol to extend its half-life; it acts as an immunomodulator by binding to type 1 interferon receptors and inducing antiviral responses in host cells[1][4]. This combination aims to enhance antiviral efficacy against HBV by targeting the virus through two distinct mechanisms.
- Brand names
- Pegasys ProClick
- Other names
- clevudinepeginterferon alfa-2a
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on clevudine + peginterferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clevudine + peginterferon.